Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | PRKACA | P17612 | 1/20 | 0.61 |
| ▸ | LTK | P29376 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317647 | 1.00 | EGFR (0.61) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL8976752 | 0.83 | EGFR (0.78) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL27645454 | 0.79 | EGFR (0.61) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL883724 | 0.79 | EGFR (0.61) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL18552030 | 0.79 | EGFR (0.61) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL27411128 | 0.76 | LMNA (0.58) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL29941271 | 0.76 | EGFR (1.00) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL8920 | 0.76 | EGFR (1.00) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL4424939 | 0.76 | ADORA3 (0.56) | EGFRABCG2DAPK3MAP4K4ABL1 | |
| SCHEMBL4751092 | 0.76 | ADORA3 (0.56) | EGFRABCG2DAPK3MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118348106-A | Application of 4-hydrazinoquinazoline in mass spectrometry detection and mass spectrometry detection method of carbonyl-containing micromolecules | 中国科学院化学研究所 | 2024-07-16 | — | — | CN | claimed |
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4596537-A1 | NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF | JD Bioscience Inc. (KR) | 2025-08-06 | — | — | EP | disclosed |
| CN-118348106-A | Application of 4-hydrazinoquinazoline in mass spectrometry detection and mass spectrometry detection method of carbonyl-containing micromolecules | 中国科学院化学研究所 | 2024-07-16 | — | — | CN | disclosed |
| CN-118348106-A | Application of 4-hydrazinoquinazoline in mass spectrometry detection and mass spectrometry detection method of carbonyl-containing micromolecules | 中国科学院化学研究所 | 2024-07-16 | — | — | CN | disclosed |
| CN-118348106-A | Application of 4-hydrazinoquinazoline in mass spectrometry detection and mass spectrometry detection method of carbonyl-containing micromolecules | 中国科学院化学研究所 | 2024-07-16 | — | — | CN | disclosed |
| CN-117999075-A | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof | 吉斯莫治疗股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024071629-A1 | NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF | (주)제이디바이오사이언스 | 2024-04-04 | — | — | WO | disclosed |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ADELAIDE, THE UNIVERSITY OF (AU) | 2006-07-20 | — | — | US | disclosed |
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2006-06-08 | — | — | US | disclosed |
| WO-2006002473-A1 | METHOD OF CONTROLLING DAMAGE MEDIATED BY ALPHA, BETA-UNSATURATED ALDEHYDES | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2006-01-12 | — | — | WO | disclosed |
| US-20050130251-A1 | Reagent for determination of hydrogen peroxide | KYOWA MEDEX CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1424554-A1 | REAGENT FOR DETERMINING HYDROGEN PEROXIDE | KYOWA MEDEX CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-0313630-B1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME | DEUTSCHES AUSSÄTZIGEN HILFSWERK E.V. (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-5084458-A | Bactericides, malaria and antitumor agents | SCHAPER KLAUS JUERGEN (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4997835-A | Bactericides, malaria, antitumor | SCHAPER KLAUS JUERGEN (DE) | 1991-03-05 | — | — | US | disclosed |
| EP-0313630-A1 | SUBSTITUTED 2-ACYLPYRIDIN-ALPHA-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME. | DEUTSCHES AUSSATZIGEN HILFSWER (DE) | 1989-05-03 | — | — | EP | disclosed |
| US-4053600-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS | SANDOZ, INC. (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR1, CCR9, CCR8 | EGFR 2287/4885ABCG2 1778/4885DAPK3 3116/4885 |
| US-20060160848-A1 | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes | ALDH2, ALDH1A1, HACL2 | EGFR 4323/4885ABCG2 2655/4885DAPK3 362/4885 |
| US-20060122178-A1 | Compounds having activity as inhibitors of apoptosis | BAD, CASP3, BAX | EGFR 2234/4885ABCG2 2650/4885DAPK3 70/4885 |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | EGFR 4198/4885ABCG2 1704/4885DAPK3 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.